Scios: Try, Try Again
Scios' corporate history has been littered with broken deals and shattered hopes. And yet the company always manages to pull itself together for one more try, finding a partner willing to take on a product most Scios-followers have written off as a failure: Auriculin.
You may also be interested in...
In the current economy, e.l.f.’s value messaging is resonating with new consumers, contributing to an 8% jump in its fiscal 2021 first-quarter sales. The company expects continued volatility, but is optimistic about its robust digital game, growing skin-care clout and a newly announced partnership with Alicia Keys that it says will yield much more than “just another celebrity beauty line.”
Most of the major orthopaedics companies beat analyst expectations in the second quarter, but the ongoing COVID-19 pandemic raises uncertainties regarding procedure volumes for the rest of this year. See what Zimmer Biomet’s CEO Bryan Hanson said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.